

Tailored Approach with DES for Long Coronary Lesions

Seung-Jung Park, MD, PhD,

Professor of Internal Medicine
Asan Medical Center, *Seoul, Korea*

How to Manage Long Lesion Intervention ?

- Long lesions > 28 mm, < 50 mm
- Very long lesions > 50 mm

What about long-term outcome ?



Stent overlapping, stent fracture are really problems ? Which stent would be better ?

- Impact of Cilostazol
- Very long lesions with extended to the small distal vessel

How to Manage Long Lesion Intervention ?




- Long lesions > 28 mm, < 50 mm
We have clear cut-off value of IVUS parameters

Diffuse lesion, <28 mm




Single long DES


Cypher 3.5mm, 33 mm in length



Sensitivity and specificity curves to identify optimal cut-off values of stent CSA



Sensitivity and specificity curves to identify optimal cut-off values of total stent length



Restenosis Rate according to Stented Length and Stent CSA by IVUS

SES Registry in Asan Medical Center

Stent length (mm)		Stent area (mm ²)	Restenosis rate	<i>P</i> value
≤ 40	and	≥ 5.5	1/284 (0.4%)	<i>P</i> < 0.001
≤ 40	or	< 5.5	3/127 (2.4%)	
> 40	or	≥ 5.5	6/ 70 (8.6%)	
> 40		< 5.5	11/62 (17.7%)	

Hong MK, Eur Heart J, 2006;27:1305

Stented Length to Predict Restenosis by QCA

Predictor	Restenosis (n=20)	No Restenosis (n=257)
■ Stented length \geq 46 mm	14 (13.5%)	90 (86.5%)
■ Stented length $<$ 46 mm	6 (3.5%)	167 (96.5%)

Sensitivity = 70%, Specificity = 65%,
Positive predictive value = 14%,
Negative predictive value = 97%

Unpublished data from LONG-DES I study

How to Manage Long Lesion Intervention ?


- Long lesions > 28 mm, < 50 mm
We have clear cut-off value of IVUS parameters
(Stent CSA 5.5mm^2 and/or Stented length < 50 mm)
 - 33 mm
 - 23 x 23 mm
 - 28 x 18 mm
 - 33 x 18 mm

Would be OK
($< 10\%$ Restenosis)

Which stent
would be better ?

Long DES-I

Lesion length : 36 mm
Stented segment length : 41mm




Long DES-II

Prospective
Multicenter
RCT


Lesion length : 36-37 mm

Stented segment length : 40-41mm



Kim YH, Long DES-II investigator, *Circulation*, 2006;114:2148-2153

Angiographic Restenosis : Cypher vs Taxus



ZEST

All Comer requiring PCI with DES for coronary lesions
in 20 Centers of Korea
(Total 2,640 patients)

Randomize 1:1:1
stratified by 1) Sites, 2) Diabetes, 3) Long lesions ($\geq 28\text{mm}$)

ENDEAVOR[®]
(N=880)

CYPER[®]
(N=880)

TAXUS Liberte[™]
(N=880)

Clinical follow-up at 12 months
Angiographic follow-up at 8 months

***Primary End-point: Target Vessel Failure (TVF) at 12 months**



Completed enrollment at Feb. 2008

How to Manage Long Lesion Intervention ?

- Long lesions > 25 mm, < 50 mm
We have clear cut-off value of IVUS parameters
- Very long lesions > 50 mm
What about long-term outcome ?
Stent overlapping, stent fracture are really problems ?




Very long lesion

> 50 mm



Very long lesion


Two DES with overlapping



2 x Cyphers 3.5mm, 33 mm

What about
Long-term Outcomes ?
(Full Metal Jacket)

Stented Segment is still Independent Predictor of Restenosis



Lee CW et al. Am J Cardiol 2006;97:506-511

Clinical Outcomes at 1 year of Very Long Lesions in RESEARCH

Stented length of 79mm (64-168)

	All (n=122)	SES (n=81)	PES (n=41)	<i>p value</i>
Death (%)	4.1	2.5	7.3	0.2
MI (%)	10.0	11.2	7.4	0.53
TVR (%)	7.5	7.5	7.6	0.96
MACE (%)	18.0	18.5	17.1	0.87

Aoki J et al, Am Heart J 2005;150:994-9

Clinical Outcomes at 1 year for Long LAD Lesions

Stented length of 64 ± 18 mm (27 PES, 39 SES)

	In-hospital (n=66)	Follow-up (n=66)
Death	0	0
Q wave	0	0
Non-Q wave	11 (16.6%)	1 (1.5%)
Thrombosis	1 (1.5%)	0
Restenosis	0	13 (19.6%)
TVR	0	10 (15%)
CABG	0	1 (1.5%)

Clinical Outcomes at 1 year of Very Long Lesions in AMC

Stented length of 72 ± 14 mm (266 SES, 86 PES)


	In-hospital (n=347)	Follow-up (n=346)
Death	1 (0.3%)	9 (2.6%)
Q wave	2 (0.6%)	3 (0.9%)
Non-Q wave	68 (19.6%)	68 (20%)
Thrombosis	2 (0.6%)	3 (0.9%)
Restenosis	0	41 (13.7%)
SES vs PES	0	11% vs 22%
TVR	2 (0.6%)	13 (3.8%)

Lee CW et al, Am J Cardiol 2006; 98 :918-922

Stent Overlapping (Full Metal Jacket)


Impact of Stent Overlapping

In-segment Restenosis Rate in Multiple Stenting



Kim YH et al, Catheter Cardiovasc Interv 2006;67:181-7

Stent-overlap did not show any difference in IVUS subgroup analysis : Long-DES I study



Stent Fracture (Full Metal Jacket)

Stent Fracture

SIRUS Angiographic Analysis

- 305 patients analyzed with 497 follow-up angiograms
 - 4 fractures identified (1.3%),
 - 3x Fracture Type 1 (0.98%)
 - 1x Fracture Type 2 (0.33%)
- All fractures occurred with multiple stents near the site of overlap, all vessels calcified including one chronic total occlusion.
- 1 ISR at that site with TLR (Type 1 Fracture – tissue growth)

Stent Fracture in Long Lesion from Long-DES II in AMC

- Angiographic analysis : 415 long lesions
- Incidence of fracture : 7 (1.7%)

Variable	Fracture (+) (N=7)	Fracture (-) (N=408)	P value
Reference diameter, mm	2.86 ± 0.21	2.82 ± 0.48	0.633
Lesion length, mm	38.4 ± 18.8	34.6 ± 11.9	0.985
Stent length, mm	42.4 ± 19.0	41.0 ± 13.1	0.928
Acute gain, In-stent, mm	2.37 ± 0.40	1.78 ± 0.53	0.005
Balloon to artery ratio	1.25 ± 0.20	1.24 ± 0.19	0.834
Late loss, In-stent	0.71 ± 0.48	0.26 ± 0.50	0.015
Restenosis, In-stent	1 (14.3 %)	29 (7.1 %)	0.411

Kim HS et al, Int J Cardiol 2008 (in press)

Incidence of TAXUS Express Stent Fracture

Study	Total	Fractures	Percentage
Taxus IV	875	2	0.23%
Taxus V	1401	12	0.86%
Taxus VI	589	2	0.34%
Altas	623	1	0.16%

How to Manage Long Lesion Intervention ?


- Long lesions > 28 mm, < 50 mm
We have clear cut-off value of IVUS parameters
- **Very long lesions > 50 mm (Full Metal Jacket)**
Long-term outcome would be acceptable (stent thrombosis rate 0.8-1.5%, TVR 4-15%)
Stent overlapping would be OK,
The incidence of stent fracture is relatively low and this is not clearly related with angiographic restenosis too.

How to Manage Long Lesion Intervention ?

- Long lesions > 28 mm, <50 mm
We have clear cut-off value of IVUS parameters
- Very long lesions >50mm
What about long-term outcome ?
Stent overlapping, stent fracture are really problems ?
- Impact of Cilostazol (Aspirin+Plavix+Cilostazol)

Angiographic Restenosis Rate at 9 months F/U

Long -DECLARE : Multicenter, Prospective Randomized study



Lee SW et al, Am J Cardiol. 2007;100:1103

Clinical Outcomes at 1 year

	Triple	Standard	P
Patients	206	200	
Death	0	1 (0.5%)	0.493
Cardiac	0	1 (0.5%)	
Non-cardiac	0	0	
MI	1 (0.5%)	1 (0.5%)	0.242
Stent thrombosis	1 (0.5%)	1 (0.5%)	1.0
Acute	0	0	
Subacute	1	0	
Late	0	1	
TLR	5 (2.4%)	16 (8.0%)	0.014
MACE	5 (2.4%)	17 (8.5%)	0.007


Lee SW et al, Am J Cardiol. 2007;100:1103

How to Manage Long Lesion Intervention ?

- Long lesions > 28 mm, < 50 mm
We have clear cut-off value of IVUS parameters
- Very long lesions > 50 mm
What about long-term outcome ?
Stent overlapping, stent fracture are really problems ?
- Impact of Cilostazol
- Very long lesions with extended to the small distal vessel

Extremely Long Lesion


CTO in distal LAD, BMS-ISR in proximal LAD



Do you believe
CABG better ?

Medical treatment is
another good
treatment modality.

How to treat the distal LAD lesion ? (very diffuse and small vessel disease) Full lesion coverage vs. Spot stenting ?



Cypher 3.0 x 33
After repeated ballooning





I do not prefer two-step procedure, but for particular this case, I would like to wait and see the changes of ischemic territory and distal coronary flow.

How to Manage Long Lesion Intervention ?

1. Shorter and Bigger, the better

Stented length < 50 mm and/or Stent CSA > 5.5 mm²

2. IVUS guided procedure may be helpful

3. Multiple overlapping would be OK

4. Triple antiplatelet therapy may be helpful to reduce the TLR and MACE



Thank You !!

summitMD.com